Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment

Reuters11-19

Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment

Labcorp Holdings Inc. has announced that its Labcorp Plasma Detect™, a tumor-informed, blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two peer-reviewed publications: Nature Medicine and Clinical Cancer Research. The studies have already been published and demonstrate the clinical utility of Labcorp Plasma Detect in cancer research. In Nature Medicine, researchers reported that the assay successfully tracked early disease progression and predicted long-term progression-free survival in patients with diffuse pleural mesothelioma undergoing immune-based treatment regimens before surgery. In Clinical Cancer Research, the assay was used to compare lymph fluid and plasma samples after head and neck cancer surgery, showing that lymph-based testing identified residual cancer more effectively than traditional methods. These findings suggest that Labcorp Plasma Detect may inform treatment strategies and improve post-surgical monitoring in cancer care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC28591) on November 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584945421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584945421","market":"nz","top_or_hot":-1,"title":"Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Labcorp Holdings Inc. has announced that its Labcorp Plasma Detect™, a tumor-informed, blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two peer-reviewed publications: Nature Medicine and Clinical Cancer Research. The studies have already been published and demonstrate the clinical utility of Labcorp Plasma Detect in cancer research. In Nature Medicine, researchers reported that the assay successfully tracked early disease progression and predicted long-term progression-free survival in patients with diffuse pleural mesothelioma undergoing immune-based treatment regimens before surgery. In Clinical Cancer Research, the assay was used to compare lymph fluid and plasma samples after head and neck cancer surgery, showing that lymph-based testing identified residual cancer more effectively than traditional methods. These findings suggest that Labcorp Plasma Detect may inform treatment strategies and improve post-surgical monitoring in cancer care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC28591) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Labcorp Holdings Inc. has announced that its Labcorp Plasma Detect™, a tumor-informed, blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two peer-reviewed publications: Nature Medicine and Clinical Cancer Research. The studies have already been published and demonstrate the clinical utility of Labcorp Plasma Detect in cancer research. In Nature Medicine, researchers reported that the assay successfully tracked early disease progression and predicted long-term progression-free survival in patients with diffuse pleural mesothelioma undergoing immune-based treatment regimens before surgery. In Clinical Cancer Research, the assay was used to compare lymph fluid and plasma samples after head and neck cancer surgery, showing that lymph-based testing identified residual cancer more effectively than traditional methods. These findings suggest that Labcorp Plasma Detect may inform treatment strategies and improve post-surgical monitoring in cancer care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC28591) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1059921491.USD","symbol_name":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL8THR4B:1","article_id":"2584945421","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584945421","pubTimestamp":1763553932,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Labcorp Holdings Inc. has announced that its Labcorp Plasma Detect, a tumor-informed, blood-based assay for detecting molecular residual disease  from circulating tumor DNA , was featured in two peer-reviewed publications: Nature Medicine and Clinical Cancer Research. The studies have already been published and demonstrate the clinical utility of Labcorp Plasma Detect in cancer research. In Nature Medicine, researchers reported that the assay successfully tracked early disease progression and predicted long-term progression-free survival in patients with diffuse pleural mesothelioma undergoing immune-based treatment regimens before surgery. In Clinical Cancer Research, the assay was used to compare lymph fluid and plasma samples after head and neck cancer surgery, showing that lymph-based testing identified residual cancer more effectively than traditional methods. These findings suggest that Labcorp Plasma Detect may inform treatment strategies and improve post-surgical monitoring in ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LH":"徕博科","LU0251142724.SGD":"Fidelity America A-SGD","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4588":"碎股","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","BK4550":"红杉资本持仓","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC"},"translate_title":"Labcorp推出Plasma Detect MRD技术，推进癌症检测和治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9},"content_text":"Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment\n    \n\n        Labcorp Holdings Inc. has announced that its Labcorp Plasma Detect™, a tumor-informed, blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two peer-reviewed publications: Nature Medicine and Clinical Cancer Research. The studies have already been published and demonstrate the clinical utility of Labcorp Plasma Detect in cancer research. In Nature Medicine, researchers reported that the assay successfully tracked early disease progression and predicted long-term progression-free survival in patients with diffuse pleural mesothelioma undergoing immune-based treatment regimens before surgery. In Clinical Cancer Research, the assay was used to compare lymph fluid and plasma samples after head and neck cancer surgery, showing that lymph-based testing identified residual cancer more effectively than traditional methods. These findings suggest that Labcorp Plasma Detect may inform treatment strategies and improve post-surgical monitoring in cancer care.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC28591) on November 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584945421","isCrawlerRequest":true}